Abbvie Inc

NYSE: ABBV
$183.09
+$1.95 (+1.1%)
Closing Price on November 27, 2024

ABBV Articles

The January 29 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest increased.
If you ever want to look for value in a sector in the stock market, then when you see Congress calling in some of the top companies to scold them for political purposes, you may want to start buying.
AbbVie reported mixed fourth-quarter financial results after the markets closed Thursday.
AbbVie is scheduled to report its fourth-quarter financial results before the markets open Friday.
The January 15 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest was mixed.
The Wall Street firms we cover are well aware of investor anxiety, yet they, unlike financial media talking heads, realize investors can’t just go to cash with a snap of their fingers.
The short interest data have been released for the December 31 settlement date. For most of the selected pharmaceutical stocks short interest was up.
In a new research note, Jefferies makes the case that earnings could give a lift to the sagging market, and with low expectations, the lift could be solid.
The short interest data have been released for the December 15 settlement date, and for most of the selected pharmaceutical stocks short interest was up.
24/7 Wall St. screened the Jefferies Franchise Picks list for the top-yielding stocks and found four with outstanding growth potential.
The November 30 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was up.
Brokerage firm Jefferies has released its top pharmaceutical picks for the coming year and what to expect.
The Franchise Picks list makes sense for solid growth investors looking for total return. Many of the stocks pay good dividends and have upside price potential.
Tuesday's top analyst upgrades, downgrades and initiations include AbbVie, CDW, CSC, Eli Lilly, Ericsson, Gold Fields, JD.com, Nokia and Rackspace.
Buying high-yielding blue chips for 2016 makes good sense. The Federal Reserve interest rate increases over the next two years are expected to remain very small and very measured.